BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 26721895)

  • 1. Whole exome sequencing reveals a C-terminal germline variant in CEBPA-associated acute myeloid leukemia: 45-year follow up of a large family.
    Pathak A; Seipel K; Pemov A; Dewan R; Brown C; Ravichandran S; Luke BT; Malasky M; Suman S; Yeager M; ; ; Gatti RA; Caporaso NE; Mulvihill JJ; Goldin LR; Pabst T; McMaster ML; Stewart DR
    Haematologica; 2016 Jul; 101(7):846-52. PubMed ID: 26721895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia.
    Pabst T; Eyholzer M; Haefliger S; Schardt J; Mueller BU
    J Clin Oncol; 2008 Nov; 26(31):5088-93. PubMed ID: 18768433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia.
    Hollink IH; van den Heuvel-Eibrink MM; Arentsen-Peters ST; Zimmermann M; Peeters JK; Valk PJ; Balgobind BV; Sonneveld E; Kaspers GJ; de Bont ES; Trka J; Baruchel A; Creutzig U; Pieters R; Reinhardt D; Zwaan CM
    Haematologica; 2011 Mar; 96(3):384-92. PubMed ID: 21134981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease evolution and outcomes in familial AML with germline CEBPA mutations.
    Tawana K; Wang J; Renneville A; Bödör C; Hills R; Loveday C; Savic A; Van Delft FW; Treleaven J; Georgiades P; Uglow E; Asou N; Uike N; Debeljak M; Jazbec J; Ancliff P; Gale R; Thomas X; Mialou V; Döhner K; Bullinger L; Mueller B; Pabst T; Stelljes M; Schlegelberger B; Wozniak E; Iqbal S; Okosun J; Araf S; Frank AK; Lauridsen FB; Porse B; Nerlov C; Owen C; Dokal I; Gribben J; Smith M; Preudhomme C; Chelala C; Cavenagh J; Fitzgibbon J
    Blood; 2015 Sep; 126(10):1214-23. PubMed ID: 26162409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The +37 kb Cebpa Enhancer Is Critical for Cebpa Myeloid Gene Expression and Contains Functional Sites that Bind SCL, GATA2, C/EBPα, PU.1, and Additional Ets Factors.
    Cooper S; Guo H; Friedman AD
    PLoS One; 2015; 10(5):e0126385. PubMed ID: 25938608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hereditary acute myeloid leukemia associated with C-terminal CEBPA germline variants.
    Harrigan AM; Trottier AM
    Fam Cancer; 2023 Jul; 22(3):331-339. PubMed ID: 36879149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A family harboring a germ-line N-terminal C/EBPalpha mutation and development of acute myeloid leukemia with an additional somatic C-terminal C/EBPalpha mutation.
    Nanri T; Uike N; Kawakita T; Iwanaga E; Mitsuya H; Asou N
    Genes Chromosomes Cancer; 2010 Mar; 49(3):237-41. PubMed ID: 19953636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute myeloid leukemia due to germline CEBPA mutation in a Syrian family.
    Wafa A; Ali B; Moassass F; Kheder M; Aljapawe A; Al-Halabi B; Mrasek K; Liehr T; Al-Achkar W
    Mol Genet Genomic Med; 2022 Feb; 10(2):e1854. PubMed ID: 35032366
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Mannelli F; Ponziani V; Bencini S; Bonetti MI; Benelli M; Cutini I; Gianfaldoni G; Scappini B; Pancani F; Piccini M; Rondelli T; Caporale R; Gelli AM; Peruzzi B; Chiarini M; Borlenghi E; Spinelli O; Giupponi D; Zanghì P; Bassan R; Rambaldi A; Rossi G; Bosi A
    Haematologica; 2017 Mar; 102(3):529-540. PubMed ID: 28250006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Laboratory evaluation and prognostication among adults and children with CEBPA-mutant acute myeloid leukemia.
    Mendoza H; Podoltsev NA; Siddon AJ
    Int J Lab Hematol; 2021 Jul; 43 Suppl 1():86-95. PubMed ID: 34288448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells.
    Lin LI; Chen CY; Lin DT; Tsay W; Tang JL; Yeh YC; Shen HL; Su FH; Yao M; Huang SY; Tien HF
    Clin Cancer Res; 2005 Feb; 11(4):1372-9. PubMed ID: 15746035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA).
    Preudhomme C; Sagot C; Boissel N; Cayuela JM; Tigaud I; de Botton S; Thomas X; Raffoux E; Lamandin C; Castaigne S; Fenaux P; Dombret H;
    Blood; 2002 Oct; 100(8):2717-23. PubMed ID: 12351377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Analysis of CEBPA mutation in acute myeloid leukemia].
    Zhang Y; Zhang SJ; Qiu HX; Qiao C; Sun HM; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Aug; 18(4):859-62. PubMed ID: 20723288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.
    Green CL; Koo KK; Hills RK; Burnett AK; Linch DC; Gale RE
    J Clin Oncol; 2010 Jun; 28(16):2739-47. PubMed ID: 20439648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Investigation and clinical analysis of a family with germline CEBPA mutations in acute myeloid leukemia].
    Zhang JP; Lin D; Wang SC; Li Y; Chen YM; Wang Y; Wei H; Mi YC; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2020 Dec; 41(12):1008-1012. PubMed ID: 33445848
    [No Abstract]   [Full Text] [Related]  

  • 16. Another pedigree with familial acute myeloid leukemia and germline CEBPA mutation.
    Renneville A; Mialou V; Philippe N; Kagialis-Girard S; Biggio V; Zabot MT; Thomas X; Bertrand Y; Preudhomme C
    Leukemia; 2009 Apr; 23(4):804-6. PubMed ID: 18946494
    [No Abstract]   [Full Text] [Related]  

  • 17. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia.
    Pabst T; Mueller BU; Zhang P; Radomska HS; Narravula S; Schnittger S; Behre G; Hiddemann W; Tenen DG
    Nat Genet; 2001 Mar; 27(3):263-70. PubMed ID: 11242107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GATA2 mutations in patients with acute myeloid leukemia-paired samples analyses show that the mutation is unstable during disease evolution.
    Hou HA; Lin YC; Kuo YY; Chou WC; Lin CC; Liu CY; Chen CY; Lin LI; Tseng MH; Huang CF; Chiang YC; Liu MC; Liu CW; Tang JL; Yao M; Huang SY; Ko BS; Hsu SC; Wu SJ; Tsay W; Chen YC; Tien HF
    Ann Hematol; 2015 Feb; 94(2):211-21. PubMed ID: 25241285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GATA2 mutations in sporadic and familial acute myeloid leukaemia patients with CEBPA mutations.
    Green CL; Tawana K; Hills RK; Bödör C; Fitzgibbon J; Inglott S; Ancliff P; Burnett AK; Linch DC; Gale RE
    Br J Haematol; 2013 Jun; 161(5):701-705. PubMed ID: 23560626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML.
    Barjesteh van Waalwijk van Doorn-Khosrovani S; Erpelinck C; Meijer J; van Oosterhoud S; van Putten WL; Valk PJ; Berna Beverloo H; Tenen DG; Löwenberg B; Delwel R
    Hematol J; 2003; 4(1):31-40. PubMed ID: 12692518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.